CardioDigital
Inc Established in US (March 2007)
The
US venture, CardioDigital Inc, has been set up in Portland, Oregon,
as the vehicle for the commercialisation of near-to-market technologies
developed by the Scottish company. CardioDigital Inc will carry
out the final product design and development and market entry, while
the UK operation will expand to provide the high-tech engineering
skills necessary to bring its range of unique blood pressure and
respiratory technologies to market.
CardioDigital
Inc is staffed by a number of hand-picked experienced individuals,
headed up by Peter Galen, well known in the industry with vast experience
both in North America and Asia in getting devices to market. The
complimentary skills of the teams on both sides of the Atlantic
will ensure success in taking high quality products of significant
clinical need to the marketplace.
Blood
Pressure Purchase Strengthens CardioDigital's Portfolio (February
2007)
CardioDigital
Ltd announced today that it has successfully acquired a technology
portfolio relating to continuous non-invasive blood pressure (CNIBP)
measurement from Canadian firm VSM MedTech of Vancouver, British
Columbia.
For
the full press release click
here.
CardioDigital receives £0.5M cash injection to revolutionise
AF treatment (July 2006)
Atrial
Fibrillation (AF) is a heart condition which is highly prevalent
in the elderly population causing fatigue, breathlessness and higher
risk of stroke. Its management consumes around 1% of the total NHS
budget in the UK. The Wellcome Trust, the UK's largest biomedical
charity, has awarded £0.5M to CardioDigital Ltd to revolutionise
the treatment of this common heart condition.
For
the full press release click
here.
CD Secures Business Development Funding (April 2006)
CardioDigital
has secured further business development funding from the Wellcome
Trust, its principle shareholder. This will enable the Company to
meet all its strategic business objectives over the coming year.
AF Study Concluded (September 2005)
A
feasibility study into the applicability of CardioDigital's technologies
to ECGs' from patients presenting with Atrial Fibrillation has been
concluded. The results are very encouraging and this exciting new
development provides a natural expansion of the Company's current
technology portfolio. Full disclosure of the results will be made
in the coming months.
Professor
David Simpson (August 2005)
Professor
David Simpson has been engaged as a consultant to CardioDigital's
Board of Directors. From starting Hewlett Packards UK business,
through his presidency of Gould Inc, to the chairing of 26 new high-tech
companies David brings with him a whole spectrum of business experience.
For more information click
here.
New
CEO takes the reigns (June 2005)
As
CardioDigital's technologies move towards market readiness former
Technical Director Professor Paul Addison has been appointed full
time CEO of the company. Former part-time CEO Brendan McGuckin retains
his position as Chairman of the Board.
Management
Team Expanded (January 2005)
Dr
Gordon Forrest has been recruited as a consultant to CardioDigital's
Board of Directors. Gordon has a wealth of experience in the medical
device sector especially in diagnostics and early stage, high growth
companies. For more information click
here.
Milestones
Achieved (January 2005)
With
all technical milestones having been achieved, the third tranche
of investment from the Wellcome
Trust Technology Transfer Group has been received
PlethRESP
Demonstration Device
(August 2004)
This
month saw the completion of a demonstration device incorporating
version 1 of CardioDigital's PlethRESP Technology.
COP
Technology Launch (May 2004)
CardioDigital
launches COP
technology, a robust tool for the prediction of shock outcome during
ventricular fibrillation. 'Utilizing the full power of the unique
spectral- temporal analysis offered by the wavelet transform, this
tool supersedes the abilities of alternative methods in the market
place.' states Professor Paul Addison, Technical Director. See our
Research Section for
more information on this groundbreaking technology.
Milestones
Achieved (January 2004)
With
all technical milestones having been achieved, the second tranche
of investment from the Wellcome
Trust Technology Transfer Group has been received.
New
Technologist (July 2003)
A
new Research Technologist, Nopadol Uchaipichat, has been appointed.
Nopadol graduated with a B.Eng. (Electrical Engineering) from Kasetsart
University, Thailand, in 1997. Since then he has undertaken a PhD
degree studying the prediction of defibrillation success for patients
suffering form ventricular fibrillation. Nopadol has joined the
CardioDigital team to apply his skills to the identification of
optimal shock timing during the defibrillation process.
Recruitment
Continues (May 2003)
CardioDigital
have appointed new project co-ordinator. Philippa Boyle will take
on the administrative tasks involved in running two large projects
as well as general clerical responsibilities within company. Philippa
arrives with a wealth of experience in this field as well as a Biology
Degree from the Open University.
|